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The global incidence of melanoma has dramatically increased during the recent decades,
yet the advancement of primary and adjuvant therapies has not kept a similar pace. The
development of melanoma is often centered on cellular signaling that hyper-activates sur-
vival pathways, while inducing a concomitant blockade to cell death. Aberrations in cell
death signaling not only promote tumor survival and enhanced metastatic potential, but
also create resistance to anti-tumor strategies. Chemotherapeutic agents targetmelanoma
tumor cells by inducing a form of cell death called apoptosis, which is governed by the BCL-2
family of proteins.The BCL-2 family is comprised of anti-apoptotic proteins (e.g., BCL-2, BCL-
xL, andMCL-1) and pro-apoptotic proteins (e.g., BAK, BAX, and BIM), and their coordinated
regulation and function are essential for optimal responses to chemotherapeutics. Here we
will discuss what is currently known about the mechanisms of BCL-2 family function with a
focus on the signaling pathways that maintain melanoma tumor cell survival. Importantly,
we will critically evaluate the literature regarding how chemotherapeutic strategies directly
impact on BCL-2 family function and offer several suggestions for future regimens to target
melanoma and enhance patient survival.
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INTRODUCTION
Skin cancer is one of the leading causes of death worldwide.
Presently in the United States, it is estimated that one in
ﬁve people will develop some form of skin cancer due to a
combination of family history, environment, and genetic fac-
tors (see the American Cancer Society for more information,
http://www.cancer.org/Cancer/SkinCancer-Melanoma/Detailed
Guide/melanoma-skin-cancer-risk-factors). DNA damage caused
by ultraviolet irradiation is thought to be the main environmental
culprit behind the development of this disease. Likewise, genetic
disruption of genes necessary for the appropriate balances between
survival,proliferation, and cell death are frequently associatedwith
the development and persistence of cells that result in skin can-
cer. These cancerous cells may also develop mechanisms to evade
the immune system resulting in unimpeded cell proliferation, sur-
vival, and metastases. Malignant melanoma is the deadliest form
of skin cancer, and it arises from the uncontrollable cell division
of the basal layer melanin-producing cells called melanocytes (for
in-depth review, see Ibrahim and Haluska, 2009). Melanoma com-
monly involves the skin, but it can occur at other sites such as
the eyes, ears, and gastrointestinal tract. While melanoma only
accounts for 5% of skin cancers, it is responsible for the major-
ity of skin cancer deaths (Jemal et al., 2009). The prognosis of
melanoma is favorable when limited to the skin and wide excision
is curative. However, the prognosis of metastatic melanoma is very
poor with a 5-year survival rate of less than 20%. Presently, the
most used anti-tumor strategy for stage IV metastatic melanoma
is dacarbazine (DITC), which as a single treatment is not very
effective, and is associated with <20% response rate (Tsao et al.,
2004). Adjuvant and combination treatments are also used; for
example, cisplatin, vinblastine, and DTIC (the regimen is referred
to as “CVD”), in combination with interferon alpha-2α (IFNα)
and interleukin-2 (IL-2), but none have proven to be signiﬁcantly
effective, yet they demonstrate substantial toxicity (Legha et al.,
1989, 1996; Phan et al., 2001). In the majority of cases where a
response does occur, there is often recurrence of the cancer within
months. A better understanding of the pathways that are activated
to promote melanoma, and targeted during treatment, will hope-
fully reveal novel therapeutic opportunities. Toward the end of our
discussion, we will propose that manipulating the BCL-2 family
and the mitochondrial pathway may offer a potential therapeutic
inroad to treatment success.
THE MITOCHONDRIAL PATHWAY OF APOPTOSIS
In response to chemotherapeutics, cells attempt to eliminate the
damage or recover from it by engaging stress response pathways
(e.g., the p53 pathway), but often the damage is overwhelming, and
the treated cells induce a form of programmed cell death known as
apoptosis (Green and Evan, 2002). Apoptotic signaling can initi-
ate from outside the cell via plasma membrane receptors (referred
to as the “extrinsic pathway”; e.g., CD95/FAS or tumor necro-
sis factor receptor, TNFR), or through stress that originates from
within the cell (referred to as the“intrinsic”or “mitochondrial path-
way”; e.g., macromolecular damage; Guicciardi and Gores, 2009;
Chipuk et al., 2010). The extrinsic apoptotic pathway is engaged
when pro-apoptotic ligands such as TNFα or CD95L/FASL trigger
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death receptor signaling which directly leads to the activation
of caspases, which are the cysteine–aspartic proteases responsi-
ble for inducing the apoptotic phenotype (e.g., DNA laddering,
loss of plasma membrane asymmetry, and cellular blebbing; Pop
and Salvesen, 2009). The intrinsic pathway is triggered by intra-
cellular stress signals such as DNA damage, oncogenes, hypoxia,
and growth factor withdrawal (Chipuk et al., 2010). These cellu-
lar stressors transcriptionally and post-transcriptionally regulate
the B cell CLL/lymphoma-2 (BCL-2) family of proteins, which are
responsible formitochondrial integrity, subsequent caspase activa-
tion, and apoptosis. While these two general pathways are distinct,
there are situations of cross-talk where the extrinsic pathway pro-
motes apoptosis through the intrinsic pathway and vice versa. In
these situations, the BCL-2 family of proteins is also crucial con-
trol points of cellular fate. For the most part, cancer cells utilize
and respond to chemotherapeutic agents by regulating the mito-
chondrial pathway of apoptosis, so our discussions will be focused
on these signaling mechanisms (Figure 1).
Once the apoptotic program has been initiated by compromis-
ing the outer mitochondrial membrane (OMM), pro-apoptotic
factors are released from the mitochondrial intermembrane space
(IMS), including cytochrome c (Figure 1; Liu et al., 1996).
Monomeric apoptotic protease activating factor 1 (APAF-1) coop-
erates with cytochrome c and dATP to form the oligomeric caspase
activation platform referred to as the“apoptosome”(Li et al., 1997;
Zou et al., 1997). The apoptosome recruits,dimerizes,and activates
pro-caspase-9, which then promotes the downstream function of
pro-caspases-3, -6, and -7 (Figure 1). Often, this step in the mito-
chondrial pathway is referred to as “the point of no return,” as
mitochondrial function and ATP generation gradually wane, and
proteolytic cleavage of caspase substrates ensues. Caspase activ-
ity is responsible for the morphological phenotypes of apoptosis,
including DNA laddering, loss of plasma membrane asymmetry,
and phagocytosis (Figure 1; Logue and Martin, 2008). Regulation
of the mitochondrial pathway of apoptosis plays a crucial role
in the development and treatment of melanoma; and it has been
shown that defects in this pathway can result in resistance to tumor
suppressor pathways and treatments (for an in-depth review, see
Soengas and Lowe, 2003).
THE BCL-2 FAMILY OF PROTEINS
The involvement of mitochondria in apoptosis was ﬁrst suggested
when caspase activity resulted from Xenopus oocyte extract co-
incubation with puriﬁed mitochondria (Newmeyer et al., 1994).
FIGURE 1 |The mitochondrial pathway of apoptosis. Following cellular
stress such as DNA damage, the BCL-2 family of proteins is regulated by
transcriptional (increased or decreased) and post-translational (e.g.,
phosphorylation, cleavage, and relocalization) mechanisms. If the cellular
stress is irreparable, the culmination of pro-apoptotic signaling will lead to
mitochondrial outer membrane permeabilization (MOMP), which allows for
the release of soluble intermembrane space proteins, including cytochrome c.
APAF-1, cytochrome c, and dATP then coordinate to promote APAF-1
oligomerization and recruitment of pro-caspase-9; this complex is referred to
as the “apoptosome.”The apoptosome allows for pro-caspase-9 dimerization
and activation, and the subsequent cleavage and activation of executioner
caspases (caspase-3, -6, and -7). These caspases promote the characteristic
phenotypes of apoptosis, e.g., chromatin condensation, DNA laddering, and
plasma membrane blebbing, by cleaving numerous intracellular substrates.
Within the body, apoptotic cells are rapidly cleared by phagocytosis to ensure
tissue homeostasis.
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This activity was blocked by the addition of BCL-2, suggesting that
BCL-2 could prevent mitochondrial engagement of the cytosol.
Since then, the BCL-2 family has grown to include almost 20
members that are divided into two functional classes of proteins:
anti-apoptotic and pro-apoptotic (Figure 2). Most cells express a
variety of anti-apoptotic and pro-apoptotic BCL-2 proteins, and
through the regulation of their interactions command survival or
commitment to apoptosis (for an in-depth review, see Chipuk and
Green, 2008).
Anti-apoptotic BCL-2 proteins are comprised of four BCL-2
homology domains (BH1-4) and are generally integrated within
the OMM, but may be present in other membranes like the
endoplasmic reticulum (Petros et al., 2004). BCL-2, BCL-xL, and
myeloid cell leukemia 1 (MCL-1) are the major members of the
anti-apoptotic BCL-2 repertoire that function to preserve OMM
integrity by directly binding and inhibiting the pro-apoptotic
BCL-2 proteins (Chen et al., 2005; Willis et al., 2005, 2007;
Figure 2).
The pro-apoptotic BCL-2 members are divided into effectors
(which also contain BH1-4) and the BH3-only proteins (Figure 2).
The effector proteins BAK (BCL-2 antagonist killer 1) and BAX
(BCL-2 associated x protein) homo-oligomerize into proteolipid
pores within the OMM and are required to promote MOMP and
cytochrome c release (Lindsten et al., 2000;Wei et al., 2001). How-
ever, these effectors require an activation step, upon which they
oligomerize and gain the capacity to permeabilize membranes
composed of mitochondrial lipids (Kuwana et al., 2002). Acti-
vation of BAK and BAX occurs through interaction with so-called
“direct activators” (see below), or by physico-chemical effects of
detergents,mild heat, or elevated pH (Hsu andYoule, 1997; Khaled
FIGURE 2 |The BCL-2 family of proteins.The BCL-2 family of proteins is
divided into anti-apoptotic and pro-apoptotic members. The anti-apoptotic
members include: A1, BCL-2, BCL-w, BCL-xL, and MCL-1, all of which
contain four BCL-2 homology domains (termed BH1-4). The pro-apoptotic
proteins are subdivided into “effector” and “BH3-only” members. The
effector proteins, BAK and BAX, also contain BH1-4; while the BH3-only
proteins contain only one domain, a BH3, that is required for interactions
with anti-apoptotic and effector proteins. The BH3-only proteins include:
BAD, BID, BIK, BIM, BMF, bNIP3, HRK, Noxa, and PUMA.The BH1-3
regions form the conserved “BCL-2 core” structural unit, which includes a
hydrophobic groove that binds to BH3 domains. Many of the BCL-2 family
proteins also contain a transmembrane domain (TM).
et al., 2001; Letai et al., 2002; Pagliari et al., 2005). The BH3-
only proteins act to regulate both the anti-apoptotics and effectors
(Figures 2 and 3). Two of these, BID (BH3 interacting domain
death agonist) andBIM(BCL-2 interactingmediator of cell death),
are direct activators of BAKandBAX,acting via their BH3domains
to induce oligomerization and the permeabilization function of
BAK and BAX (Wei et al., 2000; Kuwana et al., 2002, 2005; Letai
et al., 2002). The process by which BAK and BAX permeabilize the
OMMis commonly referred to as“mitochondrial outermembrane
permeabilization,” or MOMP.
The activation of BAK and BAX leading to MOMP is com-
plex and incompletely understood. Recent in vitro studies show
that activated BID and BAX bind to one another only in
association with membranes, and this precedes BAX oligomer-
ization, which is followed by membrane permeabilization (Lovell
et al., 2008). The accepted viewpoint is that the expression, stabil-
ity, and activation of the BH3-only proteins and their interactions
with the anti-apoptotic and effector proteins sufﬁciently links pro-
apoptotic signal transduction to MOMP(Chipuk et al., 2010).
Broadly speaking, regulation of the BH3-only proteins at the tran-
scriptional and translational levels determines the OMM integrity.
When an apoptotic signal is initiated, the anti-apoptotic BCL-
2 proteins are inhibited by the sensitizer/de-repressor BH3-only
proteins (e.g., BAD, BMF, Hrk, Noxa, and PUMA), which allows
for direct activator-induced BAK and BAX activation to promote
MOMP, and subsequent apoptosis (Figure 3). Non-BCL-2 family
direct activator proteins are also described; several reports sug-
gest a direct activator function for cytosolic p53, MAP-1, and ASC
(Tan et al., 2001; Chipuk et al., 2004; Ohtsuka et al., 2004). Fur-
thermore, controversy exists regarding the role of PUMA (p53
upregulated modulator of apoptosis) in mediating BAK and BAX
activation, as conﬂicting results suggest that PUMA is either a de-
repressor/sensitizer or direct activator BH3-only protein (Chipuk
et al., 2005; Kuwana et al., 2005; Kim et al., 2009). Finally, the
steps leading to BAK and BAX activation have been unveiled
through studies that focused on structural consequences of BIM
andBAK/BAX interactions; these structural details are discussed in
Figure 3 (Dewson et al., 2008, 2009; Gavathiotis et al., 2008, 2010).
In terms of chemotherapeutic success, pushing a cell to undergo
MOMP is suggested to enhance clinical outcomes, and this is high-
lighted by the development of small molecule inhibitors to the
anti-apoptotic BCL-2 proteins, which lower the cellular threshold
for MOMP and apoptosis (Letai, 2008). We will discuss these in
greater detail later.
MELANOMA AND THE BCL-2 FAMILY
Melanoma is notorious for chemoresistance, and there continues
to be tremendous research focused on identifying the molecular
mechanisms to explain this phenotype (for an in-depth review,
see Hocker et al., 2008). Unlike many other cancers, melanoma
rarely displays mutations within the tumor suppressor p53 path-
way, which does afford the opportunity to pharmacologically
regulate the p53 pathway through chemotherapy-induced DNA
damage and stress-responses, and we will discuss this throughout
(Hocker and Tsao, 2007). However,mutations in N-RAS [neurob-
lastoma RAS viral (v-ras) oncogene homolog] and B-RAF (v-raf
murine sarcoma viral oncogene homolog B1) are common events
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FIGURE 3 | Mechanisms of action within the BCL-2 family leading to
MOMP.The upstream involvement of the BCL-2 family in apoptosis can be
divided into two parallel activities: de-repression and sensitization. The
de-repression model begins at cellular status quo with anti-apoptotic BCL-2
proteins binding and sequestering BH3-only direct activators (e.g., BCL-2
binds BIM). In response to stress, a de-repressor BH3-only protein is induced
(e.g., BAD), which can then displace the direct activator and liberate it to
activate BAK and BAX. The sensitization model involves the preemptive
binding and inactivation of anti-apoptotic proteins by sensitizer BH3-only
proteins (e.g., BCL-2 binds BAD). This sensitization prevents the inhibition of
direct activator BH3-only proteins induced following apoptotic stimulation
(e.g., BIM), thus lowering the threshold level of direct activator necessary to
activate the effectors BAK and BAX. Unbound direct activator BH3-only
proteins function in the direct activation of BAK and BAX through a transient
interaction. These interactions lead to conformational changes involving
N-terminal rearrangement, which exposes the BH3 domain of BAK and BAX.
Activated BAK monomers pair symmetrically, and oligomerize as sets of
dimers to permeabilize the outer mitochondrial membrane leading to MOMP.
In contrast, activated BAX monomers pair asymmetrically to oligomerize and
promote MOMP.
in melanoma, which are observed in approximately 20 and 70%
of patients, respectively (Shukla et al., 1989; Davies et al., 2002;
Reifenberger et al., 2004; Edlundh-Rose et al., 2006). Additionally,
the loss of PTEN (phosphatase and tensin homolog) expression,
activationof theAKT/PI3K (phosphatidylinositol 3-kinases) path-
way, and loss of CDKN2A (cyclin-dependent kinase inhibitor 2A)
often synergize with B-RAF mutations leading to the progression
from benign nevus, primary tumor, to metastatic disease (Haluska
and Hodi, 1998; Kim, 2010; Figure 4).
Activating mutations in N-RAS and B-RAF lead to positive
inﬂuences on the cell cycle, mainly by promoting mitosis and
preventing cells from engaging their repair and stress machiner-
ies, which leads to increased stress and accumulated mutations.
Studies also suggest that the expression of AKT/PI3K is directly
correlated with melanoma progression; and PTEN expression is
subsequently lost by genetic and epigenetic mechanisms to fur-
ther promote AKT/PI3K survival pathways (Steck et al., 1997;
Tsao et al., 1998, 2000; Zhou et al., 2000; Stahl et al., 2004;
Karbowniczek et al., 2008). Indeed, a recent mouse model of
combined B-RAF V600E and PTEN loss provides in vivo evi-
dence that these two pathways are necessary and sufﬁcient to
promote metastatic melanoma formation (Dankort et al., 2009).
To counteract the proliferative signals generated from the above
circumstances, cells can engage inhibitors to the cell cycle, for
example CDKN2A, which encodes for the proteins p16INK4A
(cyclin-dependent kinase inhibitor 2A) and p14ARF (alternative
reading frame); yet CDKN2A is also mutated, genetically lost, or
epigenetically silenced in a signiﬁcant percentage of melanomas
(Castellano and Parmiani, 1999). There are numerous other genes
that are targeted during the transition between primary tumor
and metastasis; more recently, the histone variant macroH2A was
shown to suppress tumor progression of malignant melanoma
(Kapoor et al., 2010). In brief, the sum of these mutations leads to
an aggressive disease that is highly resistant to chemotherapeutics
(Figure 4).
For this discussion, we are focused on understanding how
melanomas with signiﬁcant alterations in N-RAS, B-RAF, and the
other pathways listed above fail to engage apoptosis despite aber-
rations in cellular signaling leading to unregulated proliferation
(Figure 4). How are the cellular safeguards against uncontrolled
proliferation silenced to prevent apoptosis? More importantly, can
we pharmacologically regulate these aberrant pathways to pro-
duce better responses in the clinic? The answers to both of these
questions point in the direction of the BCL-2 family of proteins.
Here, we suggest that this family of anti- and pro-apoptotic mem-
bers may be what allows for melanoma development, survival,
and chemoresistance, yet it offers a pharmacologically tractable
Achilles’ heel for successful combination/adjuvant therapies to
treat malignant melanoma. In general, there are two approaches
to block apoptosis that is normally engaged following deregu-
lated cellular proliferation: the cell may decrease the expression of
pro-apoptotic BCL-2 proteins (e.g., BAX or BIM); or the cell can
over-express anti-apoptotic BCL-2 proteins (e.g., BCL-2 or MCL-
1). In either case, the resulting phenotype is the failure to promote
BAK/BAX activation, MOMP, and apoptosis following deregu-
lated cellular proliferation cues or chemotherapeutic treatment.
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FIGURE 4 | Melanoma signaling networks, progression, and
influences by the BCL-2 family. Melanoma originates from
melanocytes in the skin that acquire a series of changes that
promote the progression from a normal phenotype to a nevus,
primary tumor, and eventual metastatic disease. Epigenetically
silenced, mutated, or deleted genes that promote disease progression are
listed and discussed throughout the text. In brief, common mutations
observed early in melanoma development are in the genes encoding N-RAS
and B-RAF, and these are often complemented by mutations in the
melanocyte regulators such as MITF and BCL-2. Subsequent changes to
PTEN, CDKN2A, and mH2A along with activating mutations of the AKT/PI3K
pathway synergize with early mutations. Subsequently, alterations in
pro-apoptotic sensitivity upstream (e.g., p53) and downstream (e.g., APAF-1)
of the mitochondrial pathway of apoptosis are suggested. In parallel to these
events, the expression and function of the BCL-2 family is altered to establish
marked resistance to pro-apoptotic stimulation: there is increased expression
of anti-apoptotic members, and coordinated downregulation of pro-apoptotic
members.
This ultimately leads to metastatic disease with poor progno-
sis and decreased long-term survival despite chemotherapeutic
intervention.
Returning to the pathways that promote melanoma develop-
ment and chemoresistance, it is widely regarded that B-RAFV600E
is the most commonly observed mutation in patients (Davies
et al., 2002; Pollock and Meltzer, 2002). This gain of function
mutation is a valine to glutamic acid substitution at codon 600,
which results in a hyper-activated kinase and subsequent marked
increases in MAPK/ERK signaling (Wan et al., 2004). Increased
B-RAF V600E activity is demonstrated to promote BIM phos-
phorylation, leading to its proteasome-mediated degradation in
several melanoma models (Cartlidge et al., 2008; Sheridan et al.,
2008; Boisvert-Adamo et al., 2009; Goldstein et al., 2009). The
B-RAFV600E mutation is observed very early in melanoma devel-
opment starting at the benign nevus stage. Therefore, reducing
BIM levels and all apoptotic pathways that BIM directly regulates
(e.g., cytokine/growth factor withdrawal) likely leads to marked
resistance to apoptosis (Bouillet et al., 1999). Likewise, since BIM
is a direct activator of BAX and BAK, chemotherapies that uti-
lize a BIM-dependent mechanism will likely not be successful
(Letai et al., 2002; Kuwana et al., 2005; Dai et al., 2008). Multiple
other pro-apoptotic BCL-2 proteins are also targeted by the B-RAF
V600E mutation. Several studies suggest that excessive signaling
through B-RAF and MAPK promotes BAD (BCL-2 antagonist of
cell death) phosphorylation and inactivation, and decreased BMF
(BCL-2 modifying factor) and PUMA expression, and all these
events lead to abrogated BAK/BAX activation, MOMP, and apop-
tosis (Cartlidge et al., 2008; Sheridan et al., 2008; Boisvert-Adamo
et al., 2009; Goldstein et al., 2009; Keuling et al., 2010; Shao and
Aplin, 2010).
There is also a growing literature connecting RAS and B-
RAF mutations to the induction of autophagy. Autophagy is
a catabolic process which promotes the degradation of cyto-
plasm and organelles; and this plays a key role in tumorigenesis
as it often helps cells cope with stress (for in-depth review,
see Kondo et al., 2005). Activating mutations in RAS and B-
RAF promote autophagy, which can restrict tumor cell growth
(Chen and Karantza-Wadsworth, 2009; Maddodi et al., 2010;
Elgendy et al., 2011). In contrast, some tumor cells display an
addiction to autophagy, which can promote glucose metabo-
lism and mitochondrial function, leading to enhanced tumori-
genesis (Guo et al., 2011; Lock et al., 2011). Interestingly, anti-
apoptotic BCL-2 proteins function at the intersection between
autophagy and apoptosis by directly regulating Beclin-1 activity, a
key protein that is required for the initiation of the formation of
the autophagy machinery. Therefore, integrating the mechanistic
interplay between the pathways that promote melanoma devel-
opment, autophagy, and the cell death machinery is of critical
importance to understanding this disease and potential therapeu-
tic strategies (Levine et al., 2008; Chipuk et al., 2010). Importantly,
the regulation of anti-apoptotic BCL-2 proteins by BH3-only pro-
teins and BH3 mimetics (discussed later) impacts not only on
apoptosis, but also autophagy, and subsequent changes to stress
signaling, proteostasis, and metabolism; yet we will focus our
discussion on cellular commitment to apoptosis.
The role of the anti-apoptotic BCL-2 proteins in melanoma is
highlighted by the phenotype of the bcl-2 knockout mouse which
displays dramatic graying of the hair because of diminished fol-
licular melanocyte survival (Yamamura et al., 1996). In support
of this phenotype, microphthalmia associated transcription fac-
tor (MITF), a key transcription factor necessary for melanocyte
development and survival, directly induces bcl-2 promoter activ-
ity (McGill et al., 2002). Elevated levels of BCL-2 and MITF can
promote chemoresistance and are associated with melanoma pro-
gression; furthermore, antisense against BCL-2 or MITF promotes
a decrease in melanoma cell survival and sensitivity to chemother-
apy (Jansen et al., 1998; Gautschi et al., 2001; McGill et al., 2002).
This leads us to ask why melanocytes are solely addicted to BCL-
2? Perhaps this cell type does not express other anti-apoptotic
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BCL-2 proteins, so small increases in BH3-only protein activity
may promote premature MOMP and apoptosis, whereas this nor-
mally tolerated level of BH3-only protein activitywould be actively
sequestered by BCL-2 to allow for stress resolution. Such a lim-
ited repertoire of anti-apoptotic reserve would not appear to
favor chemoresistance. However, the malignant transformation
and chemoresistance seen in melanomas has also been attributed
to increased levels in A1 (BCL-2 related gene A1), BCL-xL, and
MCL-1, allowing for a rather substantial shift in the apoptotic
threshold (Tang et al., 1998; Leiter et al., 2000; Zhang and Rosdahl,
2006; Placzek et al., 2010; Zhuang et al., 2010). The upregulation
of these anti-apoptotic proteins during the transition from nevus
to melanoma may indicate their active role in melanoma progres-
sion (Wong et al., 2008). Several additional transcription factors
such as ETS-1 (v-ets erythroblastosis virus E26 oncogene homolog
1), and the chromatin remodeling factor DEK, promote MCL-
1 expression, and may present novel mechanisms (and perhaps
chemotherapeutic strategies) as to the mechanism of melanoma
survival and chemoresistance (Khodadoust et al., 2009;Dong et al.,
2011).
From both in vitro and in vivo melanoma model systems, sev-
eral lines of evidence suggest that BCL-2 over-expression correlates
with a malignant phenotype and a higher metastatic potential
(Grover and Wilson, 1996; Takaoka et al., 1997; Xie et al., 1997;
Leiter et al., 2000; Utikal et al., 2002; Zhang and Rosdahl, 2006).
This seems logical, as a cell expressing more anti-apoptotic pro-
teins should resist apoptosis despite cues to die following events
from benign status to malignancy and metastasis. However, there
are conﬂicting results in the literature that describe decreasedBCL-
2 expression during melanoma progression (Saenz-Santamaria
et al., 1994; Ramsay et al., 1995; Tron et al., 1995; Tang et al.,
1998; Korabiowska et al., 1999; Sviatoha et al., 2002). Similarly,
BCL-2 is described to be constitutively expressed in melanocytes,
nevi, and melanoma, with little change in expression levels (Cer-
roni et al., 1995; Collins and White, 1995; Morales-Ducret et al.,
1995; Plettenberg et al., 1995; Miracco et al., 1998; Selzer et al.,
1998; Loggini et al., 2001; Gradilone et al., 2003). The observa-
tions in both these scenarios can be reconciled if we consider
that a cell may have the opportunity to express alternative anti-
apoptotic BCL-2 members, such as BCL-w, BCL-xL, MCL-1, or
A1. Another possibility is downregulation of the pro-apoptotic
effectors BAK and BAX, which is also associated with tumor pro-
gression and decreased patient survival (Fecker et al., 2006; Tch-
ernev andOrfanos, 2007). The balance between pro-apoptotic and
anti-apoptotic BCL-2members could also be considered to control
apoptosis. For example, the BAX/BCL-2 ratio in chemotherapy-
sensitive cells is relatively higher than in cells displaying chemore-
sistance (Raisova et al., 2001). However, great caution should be
employed with monitoring only a few proteins, as MOMP and
apoptosis proceed when multiple BH3-only proteins collaborate
to promote BAK/BAX activation. Understanding the dynamic
and total protein·protein interactions within the BCL-2 family
is more indicative of apoptotic sensitivity and chemotherapeutic
responses. This has been recently applied to tumors of lymphoid
origin, and should be developed to better delineate which patients
have the best chance of chemotherapeutic responses (Deng et al.,
2007; Ryan et al., 2010).
Returning to our original questions, it appears that melanoma
has developed numerous strategies to block apoptosis despite
heightened cellular proliferation cues: the loss of BH3-only protein
function, along with collateral increases in anti-apoptotic BCL-2
protein expression and diversity. The marked increase in anti-
apoptotic BCL-2 proteins suggests that these cells can engage a
pro-apoptotic response, and that the increased BCL-2 expression
favors a selection process where increased BCL-2 (or other anti-
apoptotic members) confers a survival advantage. Strategies that
promote BH3-only protein function, while also decreasing the
functional anti-apoptotic BCL-2 repertoire, will likely yield the
best clinical responses; indeed, we will discuss the results of such
strategies in the following sections.
MELANOMA TREATMENT AND THE BCL-2 FAMILY
Standard treatments for patients diagnosed with stage IV metasta-
tic malignant melanoma are DTIC and IL-2. The FDA approved
DTIC in 1975, and it remains the most commonly used sin-
gle agent chemotherapeutic for metastatic melanoma. DTIC is
an alkylating agent, which prevents DNA replication and sub-
sequently blocks proliferation. Unfortunately, the response rate
is less than 20% and resistance nearly always occurs (Stein and
Brownell, 2008). Other chemotherapeutic agents are currently
being studied to improve late stage melanoma treatment but few
are proving to be more effective than DTIC. For example, temo-
zolomide, a imidazotetrazine-derivative of DTIC, was tested in
clinical trials but did not improve the overall survival of patients
compared to DTIC (Patel et al., 2011). In addition to the stan-
dard combination chemotherapy regimens [e.g., CVD (cisplatin,
vinblastine, DTIC), Dartmouth (DTIC, cisplatin, carmustine, and
tamoxifen), and BOLD (bleomycin, vincristine, lomustine, and
DTIC)], a number of novel adjuvant therapies are currently
being evaluated to improve the efﬁciency of DTIC-based treat-
ments (Seigler et al., 1980; Legha et al., 1989; Lattanzi et al.,
1995). In particular, Ipilimumab, a human IgG1 monoclonal anti-
body that recognizes cytotoxic T-lymphocyte-associated antigen
4 (CTLA-4), enhances T-cell activation, proliferation, and attack
of cancer cells (Melero et al., 2007; O’Day et al., 2007; Fong
and Small, 2008; Robert and Ghiringhelli, 2009; Hodi et al.,
2010). The combination of DTIC and Ipilimumab was recently
shown to be associated with a signiﬁcant increase in survival
among patients with untreated metastatic melanoma (Robert
et al., 2011).
The mechanism of action for DTIC-based therapies is to kill
tumor cells by DNA damage, and these treatments likely signal
through the p53 pathway to induce apoptosis (Igney and Kram-
mer, 2002; Vousden and Lane, 2007). Fortunately, p53 is rarely
targeted in melanoma, so the pro-apoptotic arm of the p53 path-
way has the potential to be engaged. DTIC also directly impacts
on the BCL-2 family from several angles: there is downregula-
tion of anti-apoptotic proteins, and coordinated upregulation of
BH3-only proteins and effector molecules, like BIM and BAX,
respectively (Weber et al., 2009; Jiang et al., 2010b). Importantly,
DTIC has been studied in multiple cellular models of melanoma,
and the consistent observation is that DTIC promotes apopto-
sis through a marked regulation of the BCL-2 family leading to
MOMP. But what accounts for the low response rate of melanoma
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patients to DTIC? Can the threshold for BAK/BAX activation,
MOMP, and apoptosis be lowered to increase DTIC responses
in patients? There is minimal information regarding how combi-
nation chemotherapy regimens (e.g., CVD) impact on the BCL-2
family. It is therefore essential to better understand the mech-
anisms of action to design appropriate co-administered adjuvant
therapies. A non-exhaustive list of several chemotherapeutic drugs
(some discussed below) and their impact on the BCL-2 family in
common melanoma cell lines is provided in Table 1.
In terms of a targeted therapeutic approach, the frequency of
the B-RAF V600E mutation in melanoma presents a novel and
unique drug target (Davies et al., 2002; Sheridan et al., 2008).
Early studies with B-RAF V600E mutated melanoma lines suggest
that silencing B-RAF V600E expression leads to greater sensi-
tivity to apoptosis, which is likely mediated by the combined
stabilization and function of BIM to promote BAK/BAX activa-
tion (Jiang et al., 2010a). In recent years, treatment of melanoma
patients harboring the B-RAF V600E mutation with small mol-
ecules (e.g., PLX-4720, PLX-4032) that speciﬁcally inhibit the
B-RAF V600E kinase has been successful through Phase III
clinical trials, and appears to offer greater response rates and
increased overall survival compared to DTIC (Flaherty et al.,
2010).
However,melanoma cells treatedwith these drugs have ameans
of becoming resistant to declining levels of B-RAF signaling. For
instance, if PTEN expression or function is lost, there are sug-
gestions in the literature that melanoma cell lines can develop
resistance to PLX-4720 induced death due to decreased BIM
(Paraiso et al., 2011). The loss of PTEN results in constitutive
activation of the PI3K/AKT pathway, which has been described
in melanoma suggesting B-RAF inhibitors will only work for a
subset of patients carrying the B-RAF V600E mutation and func-
tional PTEN (VanBrocklin et al., 2009). Dual requirements for
the PI3K/AKT pathway and constitutive MAPK signaling are also
supported by combination treatments such as Sorafenib [small
molecular inhibitor of several tyrosine protein kinases (VEGFR
and PDGFR) and B-RAF] and nanoliposomal ceramide, which
have been shown to synergistically decrease PI3K/AKT and MAPK
signaling leading to increased sensitivity to the mitochondrial
pathway of apoptosis in vitro (Tran et al., 2008). Furthermore,
several MEK pathway inhibitors, such as UO126 and CI-1040,
have also been shown to cause upregulation of pro-apoptotic
BCL-2 protein function like BIM, BMF, Noxa, and PUMA, and
occasionally can lead to the downregulation of anti-apoptotic
proteins like BCL-2 and MCL-1 (Wang et al., 2007; VanBrocklin
et al., 2009). Perhaps combinations of B-RAF and MEK inhibitors
can promote more robust apoptosis due to dual regulations of
numerous anti- and pro-apoptotic BCL-2 members (Wang et al.,
2007).
From our discussion, we suggest that melanoma likely devel-
ops because of altered BCL-2 family function, which allows for
survival and proliferation despite signals to die. Likewise, litera-
ture supports that chemotherapies engage apoptosis by directly
promoting the function of pro-apoptotic BCL-2 members. If so,
are there other drugs that can be used in combination with DTIC
to alter the balance toward death, perhaps by decreasing anti-
apoptoticBCL-2protein expression,or by inhibiting their function
by inducing BH3-only proteins? Indeed, there is already an abun-
dant literature to show that many drugs can directly regulate
the BCL-2 family to favor turning on the mitochondrial path-
way of apoptosis (Table 1). Numerous DNA damaging agents,
such as cisplatin, directly impinge on the mitochondrial pathway
of apoptosis by lowering anti-apoptotic BCL-2 protein expres-
sion, while also increasing effector levels, and presumably, activa-
tion and MOMP (Shibuya et al., 2003). Endoplasmic reticulum
stress induced by tunicamycin or thapsigargin can also induce
apoptosis of melanoma cells, which has been shown to directly
up-regulate PUMA expression (Jiang et al., 2008). Proteasome
inhibitors such as bortezomib have been shown to induce BID,
Noxa, and PUMA in melanoma cells (Nikiforov et al., 2007;
Seeger et al., 2010). Drugs with diverse mechanisms of action
including dihydroartemisinin (promotes oxidative stress), ADI-
PEG20 (arginine deiminase), and aminooxyacetate (transaminase
inhibitor) appear to directly regulate Noxa expression, which has
been shown to directly impact on cellular sensitivity to both
intrinsic and extrinsic forms of apoptosis (Qin et al., 2010; You
et al., 2010; Cabello et al., 2011). The overall outcome of such
studies suggests that the BCL-2 family determines the chemother-
apeutic response to either engage apoptosis or continue with
survival. Indeed, several drugs are suggested to promote apop-
tosis via BIM, which nicely parallels existing clinical data that
shows melanoma progression and poor survival rates are asso-
ciated with decreased BIM expression (Cartlidge et al., 2008; Dai
et al., 2008). Are there strategies to sensitize melanoma cells to
chemotherapeutics by using this information? In the following
section, we provide evidence that depleting cellular anti-apoptotic
BCL-2 function may be the optimal combination therapy to
promote chemotherapeutic responses despite over-expressed anti-
apoptotic BCL-2 members or decreased pro-apoptotic BCL-2
engagement.
BCL-2 FAMILY INHIBITORS AND MELANOMA TREATMENT
RESPONSES
As mentioned, the BCL-2 family of proteins can inﬂuence both
the progression and chemotherapeutic responses of melanoma.
While conventional chemotherapeutic regimens can modulate the
levels of individual anti- and/or pro-apoptotic BCL-2 proteins,
changes in one or two proteins will likely induce only minor
effects in the pro- and anti-apoptotic balance. Furthermore, since
anti-apoptotic proteins are numerous, there are multiple mem-
bers with the potential to inhibit pro-apoptotic signaling lead-
ing to chemoresistance. While there are notions to suggest that
loss of BID/BIM or BAK/BAX can lead to cancer development
and/or chemoresistance, most data suggest that these proteins
are not commonly targeted, which affords the over-expressed
anti-apoptotic members a unique opportunity for pharmacolog-
ical regulation (Letai, 2008). With this understanding, directly
targeting the anti-apoptotic BCL-2 proteins, and indirectly the
pro-apoptotic machinery they control, is an attractive tool with
potential to generate new therapies, as well as complement exist-
ing treatments. In this endeavor, the greatest successes have come
through the identiﬁcation of small molecules that mimic the
function of BH3-only proteins to bind within the hydropho-
bic pocket of the anti-apoptotic BCL-2 proteins. These small
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Table 1 | A list of chemotherapeutics that induce changes to the BCL-2 family in various melanoma cell lines.
Cellular target Drug BCL-2 family effect Model References
Anti-oxidant/anti-
inﬂammatory?
Vernolide-A BAX Upregulation B16-F10 Pratheeshkumar and Kuttan (2011a)
BCL-2 Downregulation B16-F10 Pratheeshkumar and Kuttan (2011a)
B-RAF PLX-4720 BIM-EL Upregulation Mel-RMu (B-RAFV600E) Jiang et al. (2010a)
BIM-L Upregulation Mel-RMu (B-RAFV600E) Jiang et al. (2010a)
BIM-S Upregulation Mel-RMu (B-RAFV600E) Jiang et al. (2010a)
DNA Fotemustine PUMA Downregulation 1205Lu Weber et al. (2009)
Noxa Upregulation 1205Lu Weber et al. (2009)
Cisplatin BAX Upregulation G361 Shibuya et al. (2003)
BCL-2 Downregulation G361 Shibuya et al. (2003)
Dacarbazine BAX Upregulation A375 Jiang et al. (2010b)
BCL-XL Downregulation FEMIX-1 Lillehammer et al. (2007)
BCL-XL Downregulation A375 Jiang et al. (2010b)
BIM Upregulation 1205Lu Weber et al. (2009)
MCL-1 Downregulation FEMIX-1 Lillehammer et al. (2007)
MCL-1 Downregulation A375 Jiang et al. (2010b)
Noxa Upregulation 451Lu, 1205Lu Weber et al. (2009)
ER stress Thapsigargin BCL-2 Upregulation Mel-RM, MM200 Jiang et al. (2008)
MCL-1 Upregulation Mel-RM, MM200 Jiang et al. (2008)
Noxa Upregulation Mel-RM, MM200 Jiang et al. (2008)
PUMA Upregulation Mel-RM, MM200 Jiang et al. (2008)
Tunicamycin BCL-2 Upregulation Mel-RM, MM200 Jiang et al. (2008)
MCL-1 Upregulation Mel-RM, MM200 Jiang et al. (2008)
Noxa Upregulation Mel-RM, MM200 Jiang et al. (2008)
PUMA Upregulation Mel-RM, MM200 Jiang et al. (2008)
GST Nomilin BAX Upregulation B16-F10 Pratheeshkumar et al. (2011)
BCL-2 Downregulation B16-F10 Pratheeshkumar et al. (2011)
Hydrogen disulﬁde
donor
Diallyl trisulﬁde BCL-2 Downregulation A375, M14 Zhou et al. (2009)
BCL-XL Downregulation A375, M14 Zhou et al. (2009)
MAPK pathway UO126 BAD Upregulation Mel-RM Wang et al. (2007)
BIM-EL Upregulation Mel-RM, MM200 Wang et al. (2007)
BIM-L Upregulation Mel-RM, MM200 Wang et al. (2007)
BIM-S Upregulation Mel-RM, MM200 Wang et al. (2007)
PUMA Upregulation Mel-RM, MM200 Wang et al. (2007)
Multiple targets Phenoxodiol BAD Upregulation IgR3, ME4405 Yu et al. (2006)
BIM Upregulation IgR3, ME4405, MEL-AT, MEL-RM Yu et al. (2006)
Noxa Upregulation ME4405, MEL-AT Yu et al. (2006)
PUMA Upregulation ME4405, MEL-AT Yu et al. (2006)
NF-κB Sulforaphane BAX Upregulation B16-F10 Hamsa et al. (2011)
BCL-2 Downregulation B16-F10 Hamsa et al. (2011)
BID Downregulation B16-F10 Hamsa et al. (2011)
Gambogic acid BAX Upregulation A375 Xu et al. (2009)
BCL-2 Downregulation A375 Xu et al. (2009)
NF-κB and AP-1 Andrographolide BAX Upregulation B16-F10 Pratheeshkumar and Kuttan (2011b)
BCL-2 Downregulation B16-F10 Pratheeshkumar and Kuttan (2011b)
Oxidative stress Dihydroartemisinin Noxa Upregulation A375, G361 Cabello et al. (2011)
PUMA Upregulation A375 Cabello et al. (2011)
Peptidase Elaﬁn BAX Upregulation A2058 Yu et al. (2010)
Noxa Upregulation A2058 Yu et al. (2010)
PUMA Upregulation A2058 Yu et al. (2010)
Proteasome MG-132 MCL-1 Upregulation A375,WM852c Miller et al. (2009)
Noxa Upregulation A375,WM852c Miller et al. (2009)
(Continued)
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Table 1 | Continued
Cellular target Drug BCL-2 family effect Model References
Bortezomib BID Upregulation MeWo Seeger et al. (2010)
MCL-1 Upregulation MeWo Seeger et al. (2010)
Noxa Upregulation MeWo Seeger et al. (2010)
PUMA Upregulation MeWo Seeger et al. (2010)
Transaminase Aminooxyacetate BCL-2 Downregulation C8161, UACC3093 Qin et al. (2010)
MCL-1 Downregulation A375, C8161, UACC3039 Qin et al. (2010)
Noxa Upregulation A375, C8161, UACC3039 Qin et al. (2010)
molecules, referred to as “BH3 mimetics,” functionally neutral-
ize several anti-apoptotic proteins, thus inhibiting their ability to
sequester pro-apoptotic proteins. This strategy lowers the cellular
threshold leading to BAK/BAX activation,MOMP,and subsequent
apoptosis.
The notion that regulating BCL-2 function in melanoma could
yield enhanced responses to chemotherapeutics arose from a study
that showed bcl-2 antisense improved treatment responses and
tumor burden in a xenograft mouse model of human disease
(Jansen et al., 1998). However, the use of bcl-2 antisense adju-
vant therapy (Oblimersen sodium)with dacarbazine failed tomeet
expectations in several trials (conducted by Genta Incorporated),
although there continues to be some controversy as to whether or
not bcl-2 antisense is beneﬁcial (Jansen et al., 2000; Bedikian et al.,
2006). Independent of those results, pharmacological regulation
of anti-apoptotic BCL-2 proteins continues to be of tremendous
interest. A BH3 mimetic that has been studied with considerable
success in melanoma is the Abbott compound ABT-737 (and the
bio-available form ABT-263). Published in 2005, ABT-737 was
identiﬁed using a structural activity relationship by nuclear mag-
netic resonance (SAR by NRM) screen for compounds that could
bind within the hydrophobic groove of BCL-xL (Oltersdorf et al.,
2005). Upon its discovery, ABT-737 was determined to have high
afﬁnity for the anti-apoptotic BCL-2 proteins BCL-2, BCL-w, and
BCL-xL, but not A1 or MCL-1. ABT-737 was immediately cast as
a promising new drug candidate since it could engage multiple
anti-apoptotic BCL-2 family members, and it demonstrated min-
imal toxicity as a single agent. However, the inability of ABT-737
to inhibit MCL-1 (or A1, however, A1 has restricted expression so
the inﬂuence in cancer is far less than MCL-1),which is commonly
over-expressed in melanomas, highlighted one weakness for using
ABT-737 in melanoma, and suggested a possible mechanism by
which ABT-737 resistance may be conferred (Yecies et al., 2010).
Indeed, melanoma survival and sensitivity to chemotherapeutics
appears to be mediated by a combination of anti-apoptotic BCL-
2 members as preclinical studies using antisense oligonucleotides
against BCL-2, BCL-xL, or MCL-1 sensitized to chemotherapy-
induced apoptosis (Gautschi et al., 2001; Del Bufalo et al., 2003;
Thallinger et al., 2003).
To better understand their combined inﬂuence on cellu-
lar survival, a recent study examined the result of reduced
MCL-1 expression in combination with ABT-737 treatment
in melanoma cells (Keuling et al., 2009). Indeed, the results
showed an increased induction of apoptosis, and opened up
the possibility for pro-apoptotic synergy between ABT-737 and
classical chemotherapeutic treatments that decrease MCL-1 lev-
els. Intriguingly, such combination regimens have already yielded
a number of successful studies. For example, ABT-737 in com-
bination with the standard clinically approved anti-melanoma
drug, dacarbazine, promoted apoptosis through the induction of
Noxa, which likely synergizes with ABT-737 to fully inhibit the
anti-apoptotic repertoire (Weber et al., 2009). In a similar sce-
nario,ABT-737 synergizedwith the proteasome inhibitorMG-132,
which was also suggested to induce Noxa expression and inhibi-
tion of MCL-1 function leading to increased rates of apoptosis
(Fernandez et al., 2005; Qin et al., 2005; Miller et al., 2009). Alter-
natively, because of frequent mutations in the MAPK pathway in
melanoma, ABT-737 has also been studied in combination with
MEK and p38 inhibitors, both of which synergize to enhance the
apoptotic machinery (Cragg et al., 2008; Keuling et al., 2010).
TW-37 is another BH3 mimetic, but it has a broader range of
targets including BCL-2, BCL-xL, and MCL-1(Verhaegen et al.,
2006). Due to the ability of TW-37 to inhibit multiple members,
in particular MCL-1, it was proposed that TW-37 could syner-
gize with chemotherapeutics to promote apoptosis independently
of Noxa regulation. Indeed, when melanoma lines were treated
with TW-37 and a MEK inhibitor (U0126), signiﬁcant apopto-
sis resulted. Interestingly, the observed synergy did not occur in
normal melanocytes, suggesting that the mechanism of action was
speciﬁc to tumor cells. Curiously, the observed apoptosis was also
dependent upon the p53 pathway, which is functionally intact in
the majority of melanoma cell lines and patients.
Obatoclax is also an inhibitor to the anti-apoptotic BCL-2 fam-
ily proteins that has been studied in melanoma. First described in
2007, Obatoclax is believed to inhibit all of the anti-apoptotic
BCL-2 proteins, including MCL-1, and thus shows less resistance
to treatment thanABT-737 (Nguyen et al., 2007).While Obatoclax
has been shown to induce apoptosis as a single agent treatment
in other types of cancer, such efﬁcacy has not been observed
in melanoma, leading to the study of combination treatments
(Trudel et al., 2007). When combined with the endoplasmic retic-
ulum stressors tunicamycin or thapsigargin, increased apoptosis
was observed (Jiang et al., 2009). This synergy is likely due to Oba-
toclax functioning like a sensitizer BH3-only protein to inhibit the
anti-apoptotic BCL-2 proteins, lowering the cellular threshold for
BAK/BAX activation, and allowing the mitochondrial apoptotic
machinery to be engaged when signaled. However, it should be
noted that despite its conﬁrmed inhibiting interaction with the
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anti-apoptotic BCL-2 proteins, albeit at a higher concentrations
than ABT-737, the mechanism by which obatoclax elicits a
response is not deﬁnitive, as studies have suggested alternative
targets than the BCL-2 family (Konopleva et al., 2008).
While the above drugs target the anti-apoptotic BCL-2 pro-
teins, none of them have proven to be as effective at binding
the anti-apoptotics proteins as the BH3-only proteins themselves.
Given the importance of the BH3 domain – anti-apoptotic inter-
action, which lowers the cellular threshold of apoptosis, short
chemically synthesized peptides mimicking the different BH3-
only proteins have been generated and tested for function (Letai
et al., 2002). Indeed, BH3 domain peptides from different BH3-
only proteins revealed the distinction between direct activator and
sensitizer/de-repressor BH3-only proteins (Figure 3). The BID
and BIM BH3 domain peptides promote BAK/BAX-dependent
MOMPand cytochrome c release,whereas theBADBH3promotes
MOMP by inhibiting BCL-2, BCL-xL, and BCL-w (and revealing
BID/BIM activity, see Figure 3), and not by direct BAK/BAX inter-
actions (Chen et al., 2005; Kuwana et al., 2005). One issue that
arose with using synthetic peptides was the loss of α-helicity that
is required for protein-protein interactions between the BH3-only
proteins and the anti-apoptotics. To address this issue,non-natural
amino acids containing oleﬁn-bearing tethers were introduced
into the BH3 domain sequence, effectively “stapling” the peptide
into an α-helical form (Walensky et al., 2004, 2006). These sta-
pled BH3 domains are referred to as “stabilized α-helix of BCL-2
domains” (SAHBs), and these may serve as a new tool for design-
ing cancer therapeutics to target the BCL-2 family and enhance
endogenous BH3-only activity. For example, the BID BH3 SAHB
was shown to induce apoptosis in leukemia cells as well as inhibit
growth of human leukemia xenografts in vivo (Walensky et al.,
2004). Recently, aMCL-1BH3SAHBwasdevelopedwhich inhibits
MCL-1 with very high afﬁnity, and indeed has also been shown to
sensitize cancer cells to apoptosis (n.b., the MCL-1 SAHB uniquely
binds to the MCL-1 hydrophobic groove; Stewart et al., 2010).
The identiﬁcation of an exclusive and potent MCL-1 inhibitor is
important, given the lack of potent inhibitors that target MCL-
1 and the emergence of MCL-1 as a chemoresistance factor in a
broad range of human cancers. These developments will hopefully
serve as an additional platform to discover small molecule regula-
tors of the BCL-2 family. Presently, BH3 domain peptides have not
been examined in the context of melanoma treatment; efforts to
elucidate their potential impact would be useful for understand-
ing both the biology of melanoma, and hopefully its treatment.
Of note, BH3 mimetics also promote autophagy, alone or in com-
bination with B-RAF inhibition; and this may be a contributing
mechanism with therapeutic potential in metastatic melanoma
(Armstrong et al., 2011; Malik et al., 2011a,b).
PERSPECTIVES
Throughout our discussions, we focused on applying the mech-
anisms of action for the BCL-2 family to the regulation of
melanoma tumorigenesis, apoptosis, and treatment. As the BCL-
2 family deﬁnes the balance between life and death in normal
and cancer cells, it is reasonable to seek a full understanding of
the cellular mechanisms that control BCL-2 family function to
establish how stressed cells undergo apoptosis, and how cancer
cells resist pro-apoptotic signals to ensure survival. Here we sug-
gest that multiple anti-apoptotic BCL-2 proteins ensure survival,
and that melanocytes undergoing stress during tumorigenesis and
metastasis increase the expression and/or function of these pro-
survivalmembers. Likewise, chemotherapeutics (single agents and
combinations) must promote the inhibition of these pro-survival
members by a combination of BH3-only protein functions to
engageBAK/BAXactivation and achieve desired clinical outcomes.
While we have focused on the direct targeting of the BCL-
2 family to promote MOMP, it is important to mention that
there are also pharmacological opportunities to promote apopto-
sis both upstream and downstream of mitochondria. In particular,
the development of XIAP (X-linked inhibitor of apoptosis pro-
tein) inhibitors is critical as the increased expression of XIAP is
positively correlated with melanoma thickness, tumor progres-
sion, and chemoresistance (Chawla-Sarkar et al., 2004; Kluger
et al., 2007; Emanuel et al., 2008; Hiscutt et al., 2010). XIAP
is a potent inhibitor to the apoptotic caspases, so relieving this
apoptotic brake is predicted to lower the threshold leading to
the cell death phenotype (Eckelman et al., 2006). Indeed, the
development of SMAC (second mitochondria-derived activator
of caspases, the cellular XIAP inhibitor) mimetics to target XIAP
is shown to induce apoptosis in numerous melanoma cell lines
(Vucic et al., 2002; Zobel et al., 2006). There are also numerous
additional pathways that offer opportunities to enhance tumor
cell killing though MOMP and apoptosis. For example, epigenetic
mechanisms are implicated in melanoma survival as miR-149 and
miR-193b enhance Mcl-1 expression in nevi, patient tumor sam-
ples, and melanoma cell lines (Chen et al., 2011; Jin et al., 2011).
Histone deacetylase (HDAC) inhibitors sensitize melanoma cells
to chemotherapy through a number of mechanisms, including
suppression of the RAS/MAPK signaling pathway and enhanced
DNA damage signaling leading to apoptosis (Peltonen et al., 2005;
Kobayashi et al., 2006; Munshi et al., 2006). Furthermore, the role
of chromatinmodiﬁcationsmay offer collateralmeans of pharma-
cological intervention as the requirement for SWI/SNF complexes
in MITF regulated melanocyte-speciﬁc gene expression pathways
directly impact on BCL-2 expression, and likely sensitivity to
chemotherapeutics (de la Serna et al., 2006; Keenen et al., 2010;
Vachtenheim et al., 2010). Determining the appropriate combina-
tion treatments for each patient based on his/her individual tumor
status will likely generate the most effective treatments.
Fortunately, the cellular signaling pathways that intersect
between the survival and apoptosis cascades are numerous (e.g., B-
RAF mutation and BCL-2 over-expression; proteasome function
and MCL-1 over-expression) and this affords the pharmacolog-
ical opportunity to explore multiple combination strategies to
cure melanoma. In the future, enhanced animal models of human
disease will likely shed light upon the mechanisms that drive
melanocyte tumorigenesis and metastasis. The combined B-RAF
V600E/PTEN mouse model mentioned earlier is perhaps the ideal
model system to genetically evaluate the role of the BCL-2 fam-
ily in melanoma progression (Dankort et al., 2009). As further
models are developed, they should be evaluated along side the
standard models of BCL-2 family function (e.g., bak−/− bax−/−,
bid−/−bim−/−, puma−/−, melanocyte-speciﬁc bcl-2 and mcl-1
transgenics, etc. . .) to fully appreciate the inﬂuence of the BCL-2
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family in mediating melanoma development and treatment. Like-
wise, a better understanding of the pathways (e.g., mitochondrial
dynamics, structural studies, lipid environment etc. . .) that reg-
ulate the BCL-2 family itself will certainly yield novel target
strategies to obtain better clinical outcomes. The future shows sig-
niﬁcant promise to develop more speciﬁc and bio-available small
molecule inhibitors to the anti-apoptotic BCL-2 proteins, and per-
haps drugs that directly promote BAK/BAX activation; this will be
another signiﬁcant milestone in adjuvant-based chemotherapeu-
tic strategies targeting the mitochondrial pathway of apoptosis.
The hope is that as we further dissect the mechanisms of the
BCL-2 family and apoptotic pathways, novel therapeutic targets
and combination strategies will emerge and provide signiﬁcant
beneﬁts to those afﬂicted with melanoma.
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